Evogence Biologics
Evogence Biologics is a Finnish biotechnology startup specializing in antibody discovery and engineering for pharmaceutical applications. They utilize an enhanced mammalian display platform, developed through extensive R&D, to identify high-quality, functional antibodies. Their unique platform identifies antibodies with minimized sequence liabilities, favorable biophysical properties, and is capable of handling complex bispecific formats. Evogence Biologics offers flexible workflows and scientific excellence, tailoring antibodies to client needs with full IP ownership. Their services include antibody discovery, advanced engineering, and bispecific antibody discovery, supported by pre-selection using phage display libraries, mammalian display screening for developability, and AI-powered in-silico assessment for manufacturability. Their primary clients are biopharma companies.
Evogence Biologics
Evogence Biologics is a Finnish biotechnology startup specializing in antibody discovery and engineering for pharmaceutical applications. They utilize an enhanced mammalian display platform, developed through extensive R&D, to identify high-quality, functional antibodies. Their unique platform identifies antibodies with minimized sequence liabilities, favorable biophysical properties, and is capable of handling complex bispecific formats. Evogence Biologics offers flexible workflows and scientific excellence, tailoring antibodies to client needs with full IP ownership. Their services include antibody discovery, advanced engineering, and bispecific antibody discovery, supported by pre-selection using phage display libraries, mammalian display screening for developability, and AI-powered in-silico assessment for manufacturability. Their primary clients are biopharma companies.